Dr. Reddy's Laboratories secured European Commission approval for AVT03, a biosimilar to Prolia and Xgeva, for osteoporosis and bone complications. This significant milestone, following a positive CHMP recommendation, allows marketing across EU member states and EEA countries. Dr. Reddy's, in partnership with Alvotech, will commercialize the drug under brands Acyvbra and Xbonzy.

Dr. Reddy's Laboratories Ltd.'s price crossed above 100Day SMA today

Dr Reddy's gets marketing authorisation for biosimilar fromEuropean Commission

Business Line | 24 Nov 2025

Dr. Reddy's Laboratories Ltd.

24 Nov 2025

1279.30

0.46%

Policymakers-industry partnership vital for healthcare delivery: Dr Reddy's

Business Standard

Dr Reddy's Laboratories on Monday said partnerships between policymakers and industry are vital to build a future-ready healthcare system that serves millions. Satish Reddy, the chairman of the Hyderabad-based drug major, joined industry leaders at the sixth Pre-Budget Consultation chaired by Union Finance Minister Nirmala Sitharaman in the national capital. He shared his perspective on the importance of risk-based innovation funding to strengthen India's pharmaceutical ecosystem and accelerate breakthroughs that improve patient access and affordability. "At Dr Reddy's, we believe that partnerships between policymakers and industry are vital to building a future-ready healthcare system that serves millions," Reddy said in a post shared by the drug firm on social networking platform LinkedIn.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

24 Nov 2025

1279.30

0.46%

Dr Reddy's Gets European Nod For Biosimilar To Treat Osteoporosis

NDTV Profit

Prolia is a prescription medicine used to treat osteoporosis in women who have been through menopause and in men who are at increased risk of fractures.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

10 Nov 2025

1279.30

0.46%

Dr Reddy's Labs loses 2.16 cr after email fraud by cyber criminals

Business Standard

The Bengaluru police have launched a probe into a cyber fraud case where hackers allegedly infiltrated the official email communication between city-based Group Pharmaceuticals and Dr Reddy's Laboratories, Hyderabad, successfully diverting a payment of Rs 2.16 crore to a fraudulent account. According to an FIR registered by the Cyber Crime Police Station, Bengaluru City, the fraud was reported by Mahesh Babu K, a senior executive with Group Pharmaceuticals. The company stated it was expecting a payment of Rs 2.16 crore from Dr. Reddy's Laboratories for goods supplied. During the course of their business, they had supplied goods to Dr Reddy's Laboratories, and were due to receive a payment of Rs 2.16 crore, the FIR stated. However, on November 3, hackers allegedly gained unauthorised access to the email communication between the two companies and sent fraudulent emails to Dr Reddy's finance and accounts team, impersonating officials of Group Pharmaceuticals and providing false bank .

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Cyber fraudstersdupe' Dr Reddy's of 2 crore by hacking email communication

Business Line | 09 Nov 2025 1 more

Dr. Reddy's Laboratories Ltd.

06 Nov 2025

1279.30

0.46%

Dr Reddy's to leverage its products in US, Europe for growth in India, emerging markets

Business Line

With a hefty revenue of $3.8 billion in FY25, this Indian giant is making waves in 45 countries, from Asia to Africa and beyond. CEO MV Ramana shared that the focus is on exciting branded generics and innovative launches, like Tegoprazan and Linaclotide, to connect with consumers

Dr. Reddy's Laborato.. has an average target of 1281.89 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

30 Oct 2025

1279.30

0.46%

Canada notice delays Dr Reddy's semaglutide generic by up to a year

Business Standard

Health Canada's non-compliance notice may delay DRL's semaglutide generic launch by 8-12 months, say analysts; shares fall over 4 per cent on Thursday